menu
    • menu
    [{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Wesana Health \/ Undisclosed"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Undisclosed"},{"orgOrder":0,"company":"Wesana Health","sponsor":"Lucy Scientific Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Psilocybine","moa":"||Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Wesana Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wesana Health \/ Lucy Scientific Discovery","highestDevelopmentStatusID":"4","companyTruncated":"Wesana Health \/ Lucy Scientific Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Wesana Health

    Menu

    Wesana Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Lucy Scientific Discovery

                            Deal Size : $0.5 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

                            Details : Through the acquisition, Lucy adds Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CN...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : $0.4 million

                            July 05, 2023

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Lucy Scientific Discovery

                            Deal Size : $0.5 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Lucy Scientific Discovery

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health

                            Details : Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental healt...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            March 21, 2023

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Lucy Scientific Discovery

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine,Imipramine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant

                            Details : Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 22, 2022

                            Lead Product(s) : Psilocybine,Imipramine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Wesana Health

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013

                            Details : The Company received positive written responses from the FDA, outlining the requirements to open the IND and commence with clinical studies for SANA-013,for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 14, 2022

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth